Zobrazeno 1 - 10
of 2 954
pro vyhledávání: '"Alectinib"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-7 (2024)
Abstract Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare subtype of inflammatory myofibroblastic tumor, characterized to be an aggressive disease with high frequency of ALK rearrangement, rapid recurrence, and poor prognosis. Primar
Externí odkaz:
https://doaj.org/article/81268a47bb3c4a13aac672d12b7e0003
Autor:
Johana Benedetti Pedroza, Irene Carrasco García, Gala Martínez Bernal, Isabel Miras Rodriguez
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 763-772 (2024)
Introduction: Inflammatory myofibroblastic tumor (IMT) is a rare entity, classified within soft tissue sarcomas. It is an intermediate malignancy tumor, which seldom presents as metastatic disease. The treatment of choice is surgery, except in cases
Externí odkaz:
https://doaj.org/article/b4126599924348d9b506d42e44f7dab1
Autor:
Caicun Zhou, MD, PhD, You Lu, MD, Sang-We Kim, MD, PhD, Thanyanan Reungwetwattana, MD, Jianying Zhou, MD, Yiping Zhang, MD, Jianxing He, MD, PhD, Jin-Ji Yang, MD, Ying Cheng, MD, Se-Hoon Lee, MD, PhD, Jianhua Chang, MD, Jian Fang, MD, Zhe Liu, PhD, Lilian Bu, MSc, Li Qian, MD, Tingting Xu, MD, Venice Archer, MB ChB, MSc, Magalie Hilton, MSc, Mingzhu Zhou, MSc, Li Zhang, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100700- (2024)
Introduction: Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced ALK-positive NSCLC, consi
Externí odkaz:
https://doaj.org/article/0adb5b401a534eba8c323105cdaa5a38
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionAberrant expression of anaplastic lymphoma kinase (ALK) is found in 3%–7% of patients with non-small cell lung cancer (NSCLC). Alectinib is a tyrosine kinase inhibitor used as first-line treatment targeting ALK-positive tumors. We herei
Externí odkaz:
https://doaj.org/article/f74fb02c4174474a9188d6bc20b0689c
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is an extremely rare and aggressive form of inflammatory myofibroblastic tumor. Clinically, it has a high risk of relapse and peripheral organ infiltration, and it responds poorly to conventiona
Externí odkaz:
https://doaj.org/article/b5c787c134bf4cb4892f4f95f39aef5e
Publikováno v:
Cancer Reports, Vol 7, Iss 8, Pp n/a-n/a (2024)
ABSTRACT Background Anaplastic lymphoma kinase (ALK) rearrangements are rare in non‐myofibroblastic sarcoma and there is limited data on the efficacy of ALK tyrosine kinase inhibitors (TKIs) and mechanisms of resistance in these patients. Case A 58
Externí odkaz:
https://doaj.org/article/678c383a8a9547e29aafe8a830dd4f97
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-6 (2024)
Abstract Anaplastic lymphoma kinase (ALK) gene fusion is a classic driver mutation in non-small cell lung cancer (NSCLC); however, ALK double-fusion variants in NSCLC have rarely been reported. In this study, we reported a case with extremely uncommo
Externí odkaz:
https://doaj.org/article/f0fbe4cd8d744e7180f371f5bf696231
Autor:
Soichiro Sakoda, Kentaro Tanaka, Yuichiro Koga, Hironori Mikumo, Yuko Tsuchiya‐Kawano, Eiji Harada, Sadafumi Tamiya, Isamu Okamoto
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 415-418 (2024)
Abstract Metastatic inflammatory myofibroblastic tumor (IMT) is very rare and detailed reports on diagnosis and treatment are limited. Here, we report a case of metastatic IMT with ALK rearrangement. A 73‐year‐old woman was diagnosed with IMT inv
Externí odkaz:
https://doaj.org/article/83ab994b16d84da982e1f4ab5ed73ce1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mohammed Alrouji, Sabina Yasmin, Fahad A Alhumaydhi, Sharaf E. Sharaf, Moyad Shahwan, Anas Shamsi
Publikováno v:
Frontiers in Chemistry, Vol 12 (2024)
Precision medicine has revolutionized modern cancer therapeutic management by targeting specific molecular aberrations responsible for the onset and progression of tumorigenesis. ROS proto-oncogene 1 (ROS1) is a receptor tyrosine kinase (RTK) that ca
Externí odkaz:
https://doaj.org/article/d67bd3815d2f42319eb6f1df1b1997d4